Albiglutide Thorough ECG Study in Healthy Volunteers
Status:
Completed
Trial end date:
2011-12-29
Target enrollment:
Participant gender:
Summary
This study is designed to investigate the effect of treatment with albiglutide on the cardiac
repolarization (corrected QT interval) in healthy male and female subjects. Moxifloxacin, a
positive control, or moxifloxacin placebo will be given in order to validate the ability of
the study to detect a change in the corrected QT interval.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fluoroquinolones Glucagon-Like Peptide 1 Moxifloxacin Norgestimate, ethinyl estradiol drug combination rGLP-1 protein